[go: up one dir, main page]

BRPI0814097A8 - Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado - Google Patents

Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado

Info

Publication number
BRPI0814097A8
BRPI0814097A8 BRPI0814097A BRPI0814097A BRPI0814097A8 BR PI0814097 A8 BRPI0814097 A8 BR PI0814097A8 BR PI0814097 A BRPI0814097 A BR PI0814097A BR PI0814097 A BRPI0814097 A BR PI0814097A BR PI0814097 A8 BRPI0814097 A8 BR PI0814097A8
Authority
BR
Brazil
Prior art keywords
insulinotropic peptide
amino acids
modified amino
peptide derivative
terminal modified
Prior art date
Application number
BRPI0814097A
Other languages
English (en)
Inventor
Hae Song Dae
Ki Lim Chang
Hoon Kim Young
Chang Kwon Se
Sun Lee Gwan
Min Bae Sung
Youb Jung Sung
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Holdings Co Ltd
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Holdings Co Ltd, Hanmi Science Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of BRPI0814097A2 publication Critical patent/BRPI0814097A2/pt
Publication of BRPI0814097A8 publication Critical patent/BRPI0814097A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

DERIVADO DO PEPTÍDEO INSULINOTRÓPICO COM SEU AMINOÁCIDO N-TERMINAL MODIFICADO. A presente invenção se refere a um peptídeo insulinotrópico modificado no aminoácido N-terminal com uma atividade alta, e a uma composição farmacêutica compreendendo o mesmo. Os derivados de peptídeo insulinotrópicos de acordo com a presente invenção apresentam efeitos terapêuticos, que não são observados nos análogos nativos e em outros análogos de peptídeos insulinotrópicos. Portanto, os derivados de peptídeo insulinotrópico e a composição farmacêutica compreendendo os mesmos de acordo com a presente invenção podem ser utilizados de maneira eficaz para o tratamento das doenças.
BRPI0814097A 2007-07-16 2008-07-16 Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado BRPI0814097A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20070071071 2007-07-16
EP60991155 2007-11-29
PCT/KR2008/004170 WO2009011544A2 (en) 2007-07-16 2008-07-16 Insulinotropic peptide derivative wherein its n-terminal amino acid is modified

Publications (2)

Publication Number Publication Date
BRPI0814097A2 BRPI0814097A2 (pt) 2015-02-03
BRPI0814097A8 true BRPI0814097A8 (pt) 2016-01-12

Family

ID=40260219

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814097A BRPI0814097A8 (pt) 2007-07-16 2008-07-16 Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado

Country Status (21)

Country Link
US (1) US9422349B2 (pt)
EP (4) EP2390265B1 (pt)
JP (7) JP2009019027A (pt)
KR (1) KR101231431B1 (pt)
CN (2) CN104672319B (pt)
AR (1) AR067555A1 (pt)
AU (1) AU2008276762A1 (pt)
BR (1) BRPI0814097A8 (pt)
CA (3) CA2693154C (pt)
DK (1) DK2390265T3 (pt)
ES (3) ES2528347T3 (pt)
IL (1) IL203288A (pt)
MY (1) MY167486A (pt)
NZ (3) NZ596828A (pt)
PH (2) PH12014500922A1 (pt)
PT (1) PT2390265E (pt)
RU (1) RU2442792C2 (pt)
SG (3) SG10201510245SA (pt)
TW (3) TWI532496B (pt)
WO (1) WO2009011544A2 (pt)
ZA (1) ZA201000125B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
WO2010107256A2 (en) * 2009-03-20 2010-09-23 Hanmi Pharm. Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
CA2781672A1 (en) 2009-11-23 2011-05-26 Amylin Pharmaceuticals, Inc. Polypeptide conjugate
RU2422461C1 (ru) * 2010-02-09 2011-06-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Аналоги эксенатида
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
EP3028720A1 (en) 2010-09-28 2016-06-08 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
JP2014521594A (ja) 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
EP2729481B1 (en) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CN103130889A (zh) * 2012-06-15 2013-06-05 中国药科大学 一种Exendin-4类似物及其制备方法和应用
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR20140088837A (ko) * 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
MX387560B (es) 2014-03-31 2025-03-18 Hanmi Pharmaceutical Co Ltd Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
JP6987741B2 (ja) 2015-07-24 2022-01-05 ハンミ ファーマシューティカル カンパニー リミテッド 生理活性ポリペプチド結合体の製造方法
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
AU2016343775B2 (en) * 2015-10-28 2021-07-29 Tufts Medical Center Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
KR102698929B1 (ko) 2016-09-23 2024-08-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
WO2018105988A1 (ko) 2016-12-05 2018-06-14 한미약품 주식회사 면역반응이 약화된 결합체
US20200230250A1 (en) 2017-02-03 2020-07-23 Hanmi Pharm. Co., Ltd. Long-acting conjugate of a physiologically active material and use thereof
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
KR20220092446A (ko) * 2020-12-24 2022-07-01 한미약품 주식회사 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
KR20230000682A (ko) 2021-06-25 2023-01-03 한미약품 주식회사 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드
KR20230010571A (ko) 2021-07-12 2023-01-19 한미약품 주식회사 Glp-1 유사체를 함유하는 경구 투여 제형 조성물
US20250236850A1 (en) * 2022-04-08 2025-07-24 Danmarks Tekniske Universitet Histidine methyltransferase for increased peptide and protein stability

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7A (en) * 1836-08-10 Thomas Blanchard Machine for boring holes and cutting lanyard-scores in deadeyes
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ATE316100T1 (de) 1996-06-05 2006-02-15 Roche Diagnostics Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
JP2002507188A (ja) 1996-08-30 2002-03-05 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド―１（ｇｌｐ―１）またはその同族体における外科処置後の異化変調を防止するための使用
UA72181C2 (uk) * 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
NZ502592A (en) * 1997-08-08 2002-03-28 Amylin Pharmaceuticals Inc Exendin agonist peptides and their use in the treatment of type I and II diabetes
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
EP1938831A1 (en) * 1997-08-08 2008-07-02 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999043708A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
CZ2001690A3 (cs) 1998-08-28 2002-04-17 Eli Lilly And Company Způsob podávání inzulinotropních peptidů
IL155812A0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
RU2332229C2 (ru) 2002-02-20 2008-08-27 Эмисфире Текнолоджис Инк. Способ введения молекул glp-1
AU2003268621B2 (en) * 2002-10-02 2009-01-15 Zealand Pharma A/S Stabilized exendin-4 compounds
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
JP2006514035A (ja) * 2002-12-17 2006-04-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 心不整脈の予防および治療
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド 腎症の治療および予防のための組成物
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
AU2006224537A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
LT2347762T (lt) * 2005-08-19 2019-08-26 Amylin Pharmaceuticals, Llc Eksendinas, skirtas diabeto gydymui ir kūno svorio mažinimui
WO2007063907A1 (ja) 2005-11-30 2007-06-07 Shionogi & Co., Ltd. ペプチド糖鎖付加体およびそれを有効成分とする医薬
WO2008019147A2 (en) * 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
US9816387B2 (en) 2014-09-09 2017-11-14 United Technologies Corporation Attachment faces for clamped turbine stator of a gas turbine engine

Also Published As

Publication number Publication date
PH12014500922A1 (en) 2016-03-07
AR067555A1 (es) 2009-10-14
JP2015166368A (ja) 2015-09-24
DK2390265T3 (da) 2014-02-10
CN101778863A (zh) 2010-07-14
SG183033A1 (en) 2012-08-30
JP2014094948A (ja) 2014-05-22
ES2444622T3 (es) 2014-02-26
HK1207088A1 (en) 2016-01-22
US9422349B2 (en) 2016-08-23
EP2176289A2 (en) 2010-04-21
TW201311272A (zh) 2013-03-16
CA2789123A1 (en) 2009-01-22
TW200922615A (en) 2009-06-01
TWI524896B (zh) 2016-03-11
JP2009019027A (ja) 2009-01-29
EP2537861B1 (en) 2014-11-26
CA2693154C (en) 2014-09-09
TWI454276B (zh) 2014-10-01
NZ594853A (en) 2012-03-30
JP2015172058A (ja) 2015-10-01
PT2390265E (pt) 2014-02-12
ES2528346T3 (es) 2015-02-09
CA2789112A1 (en) 2009-01-22
NZ596828A (en) 2012-03-30
KR20090008151A (ko) 2009-01-21
JP6023515B2 (ja) 2016-11-09
EP2537860B1 (en) 2014-11-26
EP2390265A2 (en) 2011-11-30
BRPI0814097A2 (pt) 2015-02-03
ES2528347T3 (es) 2015-02-09
JP2013014598A (ja) 2013-01-24
JP2010533709A (ja) 2010-10-28
WO2009011544A3 (en) 2009-03-19
ZA201000125B (en) 2011-04-28
PH12014500923A1 (en) 2016-03-07
AU2008276762A1 (en) 2009-01-22
EP2390265A3 (en) 2012-03-21
CA2693154A1 (en) 2009-01-22
MY167486A (en) 2018-08-30
EP2537861A1 (en) 2012-12-26
RU2442792C2 (ru) 2012-02-20
JP2013010779A (ja) 2013-01-17
CN104672319B (zh) 2020-03-10
TW201311273A (zh) 2013-03-16
EP2390265B1 (en) 2013-11-06
KR101231431B1 (ko) 2013-02-07
JP6023516B2 (ja) 2016-11-09
US20100204451A1 (en) 2010-08-12
WO2009011544A2 (en) 2009-01-22
JP5481377B2 (ja) 2014-04-23
CA2789123C (en) 2015-01-06
CN104672319A (zh) 2015-06-03
NZ582471A (en) 2012-01-12
TWI532496B (zh) 2016-05-11
SG10201510249PA (en) 2016-01-28
EP2176289A4 (en) 2010-10-27
RU2010101232A (ru) 2011-07-27
SG10201510245SA (en) 2016-01-28
IL203288A (en) 2016-02-29
EP2537860A1 (en) 2012-12-26
CA2789112C (en) 2015-01-20

Similar Documents

Publication Publication Date Title
BRPI0814097A8 (pt) Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado
BRPI0717183B8 (pt) exendina ou análogo de exendina modificada por peg, composição e seu uso
BR112012024379A2 (pt) "peptídeos glucagon, seu uso, bem como composição farmacêutica"
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
BR112013027119A2 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
NZ592509A (en) HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
BR112013026114A2 (pt) composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
AR069136A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos
BR112012024934A2 (pt) sistemas de ablação de transgene induzida farmacologicamente
BRPI0916668A2 (pt) composições e métodos para anticorpos direcionados à proteína do complemento c5
BRPI0908887B8 (pt) composição farmacêutica líquida, recipiente farmacêutico, e, métodos para preparar e para fabricar uma composição farmacêutica
MX378856B (es) Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos.
CU23821A3 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
BR112014006684A2 (pt) análogos de glucagon
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
PE20130648A1 (es) Tratamiento del sindrome de sanfilippo tipo b
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
BR112012016330B8 (pt) ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: HANMI HOLDINGS CO., LTD. (KR)

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: A FIM DE ATENDER AS ALTERACOES DE NOME E ENDERECO REQUERIDAS ATRAVES DA PETICAO NO 20120115902/RJ, DE 13/12/2012, E NECESSARIO APRESENTAR MAIS UMA GUIA RELATIVA AO SEGUNDO SERVICO SOLICITADO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]